The label for Leqvio has also been updated to remove four adverse events based on recent safety data.
Formulary Watch
Latest News
All News
Advertisement
Express Scripts will also add Sandoz’s unbranded version of adalimumab to its National Preferred Formulary. The Humira biosimilar Amjevita was added previously.
Medicare will cover Alzheimer’s drugs with full approval, including Leqembi — if the physician and patient participate in a real-world registry trial to gather additional data.
There is a risk the inhaler wouldn’t provide the right dose.
RxPreferred will offer Yusimry, a biosimilar of Humira, at a price of $569.27 plus dispensing and shipping fees. This price represents a 92% discount off Humira’s monthly price.
Zolbetuximab is a first-in-class therapy for advanced gastric and gastroesophageal cancers. The target action date is Jan. 12, 2024.
The Magellan Rx Management CEO is replacing Ken Paulus, who has held the top job at Prime since May 2019.
The FDA is asking for more pharmacokinetic data on carbidopa, one of the drugs within IPX203. The therapy is an extended-release, oral formulation of carbidopa/levodopa.
Most of the Humira biosimilars are available with two pricing options. Of the larger PBMs, only Optum Rx so far has weighed in on a coverage decision.
Similar to Amgen’s Amjevita, Hulio will be offered at a list price of 5% below and 85% below the current Humira list price.
Advertisement
The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.
How the insurance industry denies claims; consumers confused by complexity and red tape; and how the ALS drug Relyvrio came to be.
Recent study finds that Medicaid coverage for some of the first gene and cell therapies was at times delayed and not consistent with federal requirements.
A carton of Hadlima including two pre-filled pens or two pre-filled syringes is available at a list price of $1,038.
In the revised guidance, CMS clarified aspects of the negotiation process and outlined additional opportunities for engagement during the process. CMS will publish by Sept. 1, 2023, the list of the first 10 drugs for price negotiation.
Biosimilars have the potential to lower costs, but the adoption has been slower than expected, a recent study finds.
BioMarin is offering an outcomes-based warranty that will reimburse payers up to 100% of the cost if a patient does not respond to Roctavian.
Longer-acting growth hormone reduces frequency of injections. It will be available in August.
In two small studies, patients were able to be free from insulin injections for a year or more.
Sarah Emond will continue with ICER’s efforts to assess drug cost-effectiveness and health plan access policies that began with founder Steve Pearson, M.D., who will transition to an advisor role in 2024.
The National Alliance of Healthcare Purchaser Coalitions has issued a playbook to help companies navigate what they see as a flawed PBM contracting model and lack of competition.
At issue is an ongoing review of inspection results from a third-party filling company. No issues were cited in the FDA’s complete response letter about clinical efficacy or safety.
It will be commercially available in the third quarter of 2023 and have a list price of $6,050 per vial.
Pfizer’s biologics license application (BLA) for the gene therapy fidanacogene elaparvovec has been assigned a PDUFA date in the second quarter of 2024.
Blincyto is immuno-oncology therapy that targets CD19 surface antigens on B cells to treat patients with acute lymphoblastic leukemia. Its current wholesale acquisition cost price is $4,900.15 per vial.
Now with the name Litfulo, ritlecitinib is the first oral treatment for adolescents with alopecia. It has an annual list price of $49,000.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tubeless AID Systems Boost HRQoL in Type 1 Diabetes
2
Current Guideline Definitions of Barrett’s Esophagus May Fall Short in Detecting Esophageal Cancers
3
Modeling Finds the Timing of Modafinil to Treat Narcolepsy Matters for Efficacy
4
Navigating Female Sexuality in Midlife Requires Provider Nuance and Patient Advocacy
5
